Sensorion SA Total Assets
Sensorion SA total assets. Based on the latest financial reports, Sensorion SA (ALSEN) holds total assets worth €57.89 Million EUR (≈ $67.68 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALSEN market cap for the company's overall valuation and market capitalisation.
Total Assets of Sensorion SA (2011–2025)
Total assets of Sensorion SA from 2011 to 2025. This chart illustrates how Sensorion SA's total assets have evolved over time, based on quarterly financial data. See Sensorion SA (ALSEN) share price today for real-time trading data and today's change.
Sensorion SA - Asset Composition Analysis
Sensorion SA Total Assets Breakdown (December 2025)
Sensorion SA total assets breakdown as of December 2025. Sensorion SA's total assets of €57.89 Million consist of 94.8% current assets and 5.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €26.79 Million | 35.7% |
| Accounts Receivable | €6.62 Million | 11.4% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €1.88 Million | 3.3% |
| Intangible Assets | €989.00K | 1.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Sensorion SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sensorion SA (ALSEN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sensorion SA's current assets represent 94.8% of total assets in 2025, a decrease from 98.0% in 2011.
- Cash Position: Cash and equivalents constituted 35.7% of total assets in 2025, down from 42.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is cash and equivalents at 35.7% of total assets.
Sensorion SA Competitors by Total Assets
Key competitors of Sensorion SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Sensorion SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.59 | 6.28 | 15.52 |
| Quick Ratio | 4.59 | 6.30 | 15.52 |
| Cash Ratio | 2.24 | 3.81 | 2.81 |
| Working Capital | €42.92 Million | €72.05 Million | €62.12 Million |
Sensorion SA - Advanced Valuation Insights
This section examines the relationship between Sensorion SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 2.11 |
| Asset Growth Rate (YoY) | -35.2% |
| Total Assets | €57.89 Million |
| Market Capitalization | $122.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sensorion SA's assets at a significant premium (2.11x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sensorion SA's assets decreased by 35.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sensorion SA (2011–2025)
The table below shows the annual total assets of Sensorion SA from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €57.89 Million ≈ $67.68 Million |
-35.16% |
| 2024-12-31 | €89.28 Million ≈ $104.37 Million |
+91.98% |
| 2023-12-31 | €46.50 Million ≈ $54.37 Million |
+19.45% |
| 2022-12-31 | €38.93 Million ≈ $45.51 Million |
-34.03% |
| 2021-12-31 | €59.02 Million ≈ $69.00 Million |
-13.05% |
| 2020-12-31 | €67.87 Million ≈ $79.35 Million |
+78.17% |
| 2019-12-31 | €38.09 Million ≈ $44.53 Million |
+302.37% |
| 2018-12-31 | €9.47 Million ≈ $11.07 Million |
-15.18% |
| 2017-12-31 | €11.16 Million ≈ $13.05 Million |
-5.83% |
| 2016-12-31 | €11.85 Million ≈ $13.86 Million |
-28.26% |
| 2015-12-31 | €16.52 Million ≈ $19.31 Million |
+653.59% |
| 2014-12-31 | €2.19 Million ≈ $2.56 Million |
+93.56% |
| 2013-12-31 | €1.13 Million ≈ $1.32 Million |
+199.04% |
| 2012-12-31 | €378.72K ≈ $442.76K |
+24.98% |
| 2011-12-31 | €303.01K ≈ $354.26K |
-- |
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more